Published in AIDS Rev on May 03, 2007
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci (2008) 1.25
Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS (2010) 1.00
Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol (2014) 0.93
HIV and co-infections. Immunol Rev (2013) 0.92
The role of co-infections in mother-to-child transmission of HIV. Curr HIV Res (2013) 0.90
Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med (2014) 0.88
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol (2011) 0.81
Future directions in the treatment of HIV-HBV coinfection. HIV Ther (2009) 0.79
Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana. Am J Trop Med Hyg (2011) 0.78
The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag (2008) 0.76
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 2.80
New insight in the pathobiology of hepatitis B virus infection. Gut (2012) 2.54
Hepatitis C virus resistance to protease inhibitors. J Hepatol (2011) 2.18
Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int (2010) 2.12
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology (2002) 2.01
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81
Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis (2005) 1.81
Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology (2002) 1.79
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
HBV drug resistance: mechanisms, detection and interpretation. J Hepatol (2006) 1.71
Lamivudine resistant occult HBV: implications for public health? J Hepatol (2003) 1.64
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS (2006) 1.52
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. Gut (2012) 1.47
Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol (2002) 1.45
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology (2007) 1.38
Management of treatment failure in chronic hepatitis B. J Hepatol (2012) 1.33
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol (2007) 1.28
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology (2002) 1.22
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology (2003) 1.22
Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis (2012) 1.19
Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS (2003) 1.15
The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol (2011) 1.13
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother (2007) 1.13
Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol (2003) 1.08
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology (2009) 1.07
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother (2002) 1.05
Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol (2003) 1.05
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int (2013) 1.04
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther (2009) 0.98
Increased prevalence of HBV envelope mutants in Taiwan: an emerging public health risk or a false alarm? Gastroenterology (2012) 0.98
HBV genotyping and analysis for unique mutations. Methods Mol Med (2004) 0.97
An update on HDV: virology, pathogenesis and treatment. Antivir Ther (2013) 0.97
Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther (2012) 0.97
Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ (2009) 0.95
The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int (2009) 0.95
Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol (2008) 0.95
Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol (2010) 0.95
New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology (2003) 0.94
Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr (2007) 0.93
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis (2013) 0.93
Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR. Methods Mol Med (2004) 0.90
Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology (2012) 0.89
Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol (2004) 0.88
Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology (2011) 0.87
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol (2003) 0.87
The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations? Gastroenterology (2007) 0.87
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol (2010) 0.87
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology (2008) 0.86
Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses. J Med Virol (2010) 0.86
Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol (2010) 0.86
Hepatitis B precore protein: pathogenic potential and therapeutic promise. Yonsei Med J (2012) 0.86
Changing landscape of antiviral resistance management in chronic hepatitis B. J Gastroenterol Hepatol (2008) 0.86
The new front-line in hepatitis B/D research: identification and blocking of a functional receptor. Hepatology (2013) 0.86
Hepatitis B virus: pathogenesis, viral intermediates, and viral replication. Clin Liver Dis (2004) 0.85
Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol (2006) 0.85
Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection. J Med Virol (2011) 0.84
Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management. J Gastroenterol Hepatol (2010) 0.84
Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J Clin Virol (2002) 0.83
Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region. J Hepatol (2004) 0.83
Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J Hepatol (2013) 0.82
Genotyping and genomic sequencing in clinical practice. Clin Liver Dis (2007) 0.80
Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antiviral Res (2002) 0.80
Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge? Nat Rev Gastroenterol Hepatol (2009) 0.80
Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off! Antivir Ther (2004) 0.79
Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology (2004) 0.79
Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther (2004) 0.79
Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation. J Clin Virol (2005) 0.78
Direct-acting antiviral agents for the treatment of HCV. Antivir Ther (2012) 0.78
Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations. Antivir Ther (2014) 0.78
Hepatitis B antivirals and resistance. Curr Opin Virol (2013) 0.78
Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology (2002) 0.78
Mechanisms of hepatitis B virus resistance development. Intervirology (2014) 0.78
Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits. Antiviral Res (2011) 0.78
Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. PLoS One (2011) 0.77
Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy. J Clin Microbiol (2006) 0.76
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma? Antivir Ther (2009) 0.76
Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia. J Hepatol (2013) 0.76
Therapies for hepatitis B: where to from here? Gastroenterology (2005) 0.76
Monitoring gene expression using DNA microarrays during hepatitis B virus infection. Methods Mol Med (2004) 0.75
A parsimonious method for screening drug combinations for antihepadnaviral activity using a parametric dose-response surface approach. Methods Mol Med (2004) 0.75
Longitudinal observation of viral load changes in untreated HBeAg negative chronic hepatitis B. Acta Gastroenterol Belg (2013) 0.75
Studying the treatment of chronic hepatitis B viral infection in special populations. Methods Mol Med (2004) 0.75